IRCCS Istituto Ortopedico Galeazzi, Milan, 20161, Italy.
Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, 20122, Italy.
Eur Radiol Exp. 2023 Jul 20;7(1):40. doi: 10.1186/s41747-023-00353-w.
To test the technical feasibility of an augmented reality (AR) navigation system to guide bone biopsies.
We enrolled patients subjected to percutaneous computed tomography (CT)-guided bone biopsy using a novel AR navigation system. Data from prospectively enrolled patients (AR group) were compared with data obtained retrospectively from previous standard CT-guided bone biopsies (control group). We evaluated the following: procedure duration, number of CT passes, patient's radiation dose (dose-length product), complications, and specimen adequacy. Technical success was defined as the ability to complete the procedure as planned, reaching the target center. Technical efficacy was assessed evaluating specimen adequacy.
Eight patients (4 males) aged 58 ± 24 years (mean ± standard deviation) were enrolled in the AR group and compared with 8 controls (4 males) aged 60 ± 15 years. No complications were observed. Procedure duration, number of CT passes, and radiation dose were 22 ± 5 min, 4 (median) [4, 6 interquartile range] and 1,034 ± 672 mGycm for the AR group and 23 ± 5 min, 9 [7.75, 11.25], and 1,954 ± 993 mGycm for controls, respectively. No significant differences were observed for procedure duration (p = 0.878). Conversely, number of CT passes and radiation doses were significantly lower for the AR group (p < 0.001 and p = 0.021, respectively). Technical success and technical efficacy were 100% for both groups.
This AR navigation system is safe, feasible, and effective; it can decrease radiation exposure and number of CT passes during bone biopsies without increasing duration time.
This augmented reality (AR) navigation system is a safe and feasible guidance for bone biopsies; it may ensure a decrease in the number of CT passes and patient's radiation dose.
• This AR navigation system is a safe guidance for bone biopsies. • It ensures decrease of number of CT passes and patient's radiation exposure. • Procedure duration was similar to that of standard CT-guided biopsy. • Technical success was 100% as in all patients the target was reached. • Technical efficacy was 100% as the specimen was adequate in all patients.
测试一种增强现实(AR)导航系统引导骨活检的技术可行性。
我们招募了使用新型 AR 导航系统进行经皮计算机断层扫描(CT)引导骨活检的患者。将前瞻性纳入的患者(AR 组)的数据与回顾性纳入的先前标准 CT 引导骨活检患者(对照组)的数据进行比较。我们评估了以下内容:手术时间、CT 扫描次数、患者的辐射剂量(剂量长度乘积)、并发症和标本充足性。技术成功定义为能够按计划完成手术,到达目标中心。通过评估标本充足性来评估技术疗效。
共纳入 8 例(4 例男性)年龄 58 ± 24 岁(均值 ± 标准差)的 AR 组患者,并与 8 例(4 例男性)年龄 60 ± 15 岁的对照组患者进行比较。未观察到并发症。AR 组的手术时间、CT 扫描次数和辐射剂量分别为 22 ± 5 分钟、4 次(中位数)[4,6 四分位间距]和 1034 ± 672 mGycm,对照组分别为 23 ± 5 分钟、9 次[7.75,11.25]和 1954 ± 993 mGycm。手术时间无显著差异(p = 0.878)。相反,AR 组的 CT 扫描次数和辐射剂量明显较低(p < 0.001 和 p = 0.021)。两组技术成功率和技术疗效均为 100%。
该 AR 导航系统安全、可行且有效;它可以在不增加手术时间的情况下减少骨活检中的辐射暴露和 CT 扫描次数。
该增强现实(AR)导航系统是一种安全可行的骨活检引导方法;它可以确保减少 CT 扫描次数和患者的辐射剂量。
这种 AR 导航系统是一种安全的骨活检引导方法。
它确保了 CT 扫描次数和患者辐射暴露的减少。
手术时间与标准 CT 引导活检相似。
所有患者均达到了目标,技术成功率为 100%。
所有患者的标本均充足,技术疗效为 100%。